FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

Stock Information for BioCardia Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About BioCardia Inc.

BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard Krasno
BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress
BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality
BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results
BioCardia Announces Henry Ford Health Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial
BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025
BioCardia Announces University of Wisconsin Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial
BioCardia Regains Compliance with Nasdaq Listing Requirements

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.